Watchman Alternatives: A Patient's Guide to Left Atrial Appendage Closure Options Beyond the Watchman

A 78-year-old comes into clinic with AFib, a CHA2DS2-VASc score of 5 (a high stroke-risk score), and three significant gastrointestinal bleeds in the last two years. She has been off her blood thinner since the most recent bleed because every time the team restarts it, she ends up back in the emergency room. Her stroke risk is real. Her bleeding risk is also real. Anticoagulation has become impossible. Her cardiologist talks about left atrial appendage closure as a way to reduce stroke risk without the bleeding consequences of long-term anticoagulation. The first device that comes up in the conversation is the Watchman. But she’s asking whether there are alternatives, and the answer is yes. Several options exist now, and each has its own profile.

Left atrial appendage closure is a procedure that seals off the small pouch on the side of the left atrium where most AFib-related blood clots form. With the appendage sealed, the major source of stroke-causing clots is removed, and many patients can stop long-term anticoagulation. The Watchman, made by Boston Scientific, was the first FDA-approved device for this purpose. It remains the most commonly used in the United States. But the field has expanded. The Watchman FLX is the next-generation Watchman. The Amplatzer Amulet from Abbott is a competing percutaneous device. Surgical LAA closure with the AtriClip device is a well-established alternative, especially during other heart surgery. Stand-alone thoracoscopic LAA closure is an option for selected patients.

This guide walks through what each device or technique does, when one might be chosen over another, who is a candidate, what the procedure and recovery look like, and how to think about the decision. I want you to walk in informed enough to ask the questions that get you to the right answer.

What Is the Left Atrial Appendage and Why Does It Cause Strokes?

The left atrial appendage (LAA) is a small pouch attached to the side of the left atrium (the upper-left chamber of the heart). In normal sinus rhythm, blood flows in and out of the appendage smoothly. In atrial fibrillation, the chaotic atrial rhythm slows the flow inside the appendage. Stagnant blood there can form clots. When a clot dislodges and travels into the bloodstream, it can lodge in a brain artery and cause a stroke. About 90 percent of AFib-related strokes come from clots that formed in the left atrial appendage.

What the Appendage Looks Like Inside the Heart

The left atrial appendage is a thin-walled, finger-shaped pouch that sits on the side of the left atrium. Anatomists describe four common shapes: chicken wing (most common), cactus, cauliflower, and windsock. The shape matters because it influences which closure device fits best and how easy the procedure is. Imaging before the procedure (usually a transesophageal echocardiogram, or TEE, and sometimes a cardiac CT) is used to measure the appendage and pick the right device.

Why It’s a Clot Factory in AFib

In normal rhythm, the atrium contracts crisply 60 to 100 times per minute, which keeps blood flow brisk in the appendage. In AFib, the atrium quivers at 300 to 600 beats per minute without effective contraction. Flow in the appendage slows. Stagnant blood is more likely to clot. The appendage’s narrow neck and pouch shape make it especially prone to this kind of stagnant-flow clotting.

Why Removing the Appendage Reduces Stroke Risk

If you take the source of the clots out of the picture, you take most of the stroke risk away. Studies of LAA closure show stroke reduction comparable to anticoagulation, with the major advantage that long-term blood thinners can usually be stopped after a brief post-procedure period.

How LAA Closure Compares to Blood Thinners

Anticoagulation (apixaban, rivaroxaban, warfarin, dabigatran, edoxaban) reduces AFib stroke risk by about 65 percent. It also raises bleeding risk, especially in older patients with prior bleeds, falls, kidney disease, or other risk factors. For patients who can’t tolerate anticoagulation, LAA closure offers an alternative path to stroke risk reduction without the lifelong bleeding tradeoff.

Who Is a Candidate for LAA Closure?

LAA closure makes sense for people with non-valvular AFib, an elevated stroke risk score (CHA2DS2-VASc of 2 or higher in men, 3 or higher in women), and a real contraindication to long-term blood thinners or a documented failure of blood thinners. The most common reasons people qualify are prior major bleeding (especially brain bleeds or recurrent GI bleeds), severe falls with injury, occupations with high trauma risk, and inability to tolerate blood thinners despite multiple attempts.

Common Reasons to Consider LAA Closure

Prior intracranial hemorrhage (brain bleed) is the strongest single reason. Recurrent gastrointestinal bleeds requiring hospitalization or transfusion. Severe falls with injury, especially head trauma, when continuing blood thinners poses unacceptable risk. Occupations or hobbies with high trauma risk (some forms of construction work, contact sports, motorcycle riding) when discussion with the patient confirms the risk is unacceptable. Kidney disease that makes direct oral anticoagulants difficult to dose. Pregnancy or near-pregnancy in younger AFib patients. Triple therapy (anticoagulant plus dual antiplatelet for a recent stent) where the bleeding risk has become unsustainable.

Reasons LAA Closure Isn’t Appropriate

Valvular AFib from rheumatic mitral stenosis or a mechanical heart valve usually requires anticoagulation for valve-related reasons that LAA closure doesn’t address. Active clot inside the heart on imaging needs to be resolved first. Some appendage anatomies are simply unsuitable for percutaneous devices (too small a neck, unusual angulation, multilobed); for these, surgical or thoracoscopic options may apply. End-stage cardiomyopathy with very limited life expectancy may not justify the procedural risk.

The Risk-Benefit Conversation

The decision isn’t usually clear-cut. Most candidates have a stroke risk that justifies anticoagulation, a bleeding risk that disqualifies it, and a complicated medical picture that makes any procedure carry weight. The conversation should involve a cardiologist who knows your medical history and a structural heart specialist who has done many of these procedures. A second opinion is reasonable if you’re unsure.

What Are the Current Device Options?

The current US options are Watchman FLX, Amplatzer Amulet, AtriClip (surgical), and stand-alone thoracoscopic LAA closure. The two main percutaneous (catheter-based) devices are Watchman FLX and Amulet. The two surgical options apply when percutaneous closure isn’t appropriate or when other cardiac surgery is already planned.

Watchman FLX (Boston Scientific)

The Watchman FLX is the second-generation Watchman, approved in 2020. It replaced the original Watchman in most US centers. The device is a parachute-shaped frame of nitinol (a flexible metal alloy) covered with fabric that’s deployed inside the appendage through a catheter. Once positioned, it seals the appendage opening. Over months, tissue grows over the device and incorporates it into the atrial wall.

The FLX has design improvements over the original Watchman: a fully retrievable frame that lets the operator reposition the device if it isn’t in the right spot, a more conformable design that fits a wider range of appendage shapes, and a closed distal end that reduces the risk of the device migrating after deployment.

The Watchman FLX is the most studied device, has the longest US track record, and is used by the most operators. Insurance coverage is broad. If you’ve been told you’re getting “the Watchman,” you’re almost certainly getting the FLX.

Amplatzer Amulet (Abbott)

The Amplatzer Amulet was approved in the US in 2021, after being used in Europe for several years. It uses a “lobe and disc” design: a distal lobe that anchors inside the appendage and a proximal disc that covers the appendage opening from inside the atrium. The dual-element design provides occlusion at two levels.

The Amulet’s distinguishing feature is that it often achieves complete occlusion at the time of implant. That means many patients can be discharged on dual antiplatelet therapy alone (aspirin plus clopidogrel) immediately, without the 45-day blood thinner course that follows Watchman FLX. For patients who need to avoid anticoagulation entirely, this is a meaningful advantage.

The AMULET-IDE trial randomized patients between Watchman and Amulet. Both showed similar stroke prevention efficacy. Procedural success rates and overall complication rates were similar. There were some differences in the specific complications: Amulet had a slightly higher rate of pericardial effusion (fluid around the heart) in some series, while Watchman had a slightly higher rate of device-related thrombus (clot forming on the device after implant).

AtriClip (Surgical Closure)

AtriClip is a small clip placed around the base of the left atrial appendage from outside the heart, completely closing it off. It’s most commonly placed during other cardiac surgery (coronary artery bypass grafting, valve replacement, surgical AFib ablation) and is sometimes done as a stand-alone procedure via a small thoracoscopic incision.

The LAAOS III trial established surgical LAA closure as a standard adjunct in AFib patients undergoing cardiac surgery. The trial showed a 33 percent relative reduction in stroke or systemic embolism when surgical LAA closure was added to whatever heart surgery the patient was already having. Safety profiles were similar to surgery alone.

For patients undergoing other cardiac surgery, AtriClip is now routinely offered. For patients not already having heart surgery, stand-alone surgical LAA closure is reserved for selected cases.

Stand-Alone Thoracoscopic Closure

Some patients aren’t candidates for percutaneous closure because of anatomy (the appendage is too small or too oddly shaped to seat a device), but they have a clear indication for LAA closure. For these patients, a stand-alone thoracoscopic procedure can place an AtriClip on the appendage from outside the heart through small chest incisions. The procedure is more invasive than percutaneous closure but is well-established at experienced centers.

Older Devices Worth Knowing About

The original Watchman (no longer the standard, replaced by FLX in most US centers) is still occasionally used at sites that haven’t transitioned. The Amplatzer Cardiac Plug was the European predecessor to the Amulet. LARIAT is a different technology that uses an external suture loop placed via combined percutaneous-transthoracic access; it’s used at a few US centers but is much less common than the Watchman or Amulet.

How Does the Percutaneous Procedure Actually Work?

You go to sleep under general anesthesia or get deep sedation. A TEE probe is placed through the mouth into the esophagus to image the appendage from inside. A catheter is inserted in the femoral vein in the groin and threaded up to the heart. A small needle is used to puncture the wall between the upper chambers (transseptal puncture) to get into the left atrium. The chosen device is positioned in the appendage under imaging guidance, tested, and released. The procedure usually takes 60 to 90 minutes.

Before the Procedure

You’ll come in for a pre-procedure visit with the structural heart team. They’ll review your medications, your prior bleeding events, your appendage anatomy on imaging, and the device choice. They’ll explain what to do in the days leading up to the procedure.

You’ll usually have a TEE or cardiac CT to measure the appendage and confirm the device choice. You’ll get instructions on fasting (typically nothing to eat or drink after midnight) and on which medications to hold (some anticoagulants are continued, others held the morning of).

Day of the Procedure

You’ll arrive at the hospital 1 to 2 hours before the scheduled procedure. The team will place an IV, take blood for labs, and do a final check-in. You’ll meet the anesthesiologist and the structural heart team. You’ll change into a gown.

In the procedure room, you’ll lie on a narrow table. The team will give you sedation or general anesthesia. A TEE probe will be placed into your esophagus (you’ll be asleep when this happens). The team will prep your groin with antiseptic and place a sheath in the femoral vein.

A catheter goes up through the femoral vein to the right atrium. A small puncture is made through the wall between the right and left atria (transseptal puncture). The catheter advances into the left atrium and points toward the appendage. The chosen device is loaded onto the delivery system, advanced to the appendage, positioned with TEE and fluoroscopy guidance, tested for stability and seal, and released. The catheters come out. The groin site is closed with manual pressure or a closure device.

Recovery in the Hospital

You’ll wake up in a recovery area. Most patients stay 4 to 6 hours flat in bed to let the groin seal. Some teams discharge same day, others observe overnight. You’ll be on a heart monitor.

The TEE probe is removed before you fully wake up; you may have mild throat soreness afterward. The groin site will have a small dressing.

Going Home

You’ll get printed instructions on activity restrictions, medications, and follow-up. The first 24 to 48 hours, expect to feel tired. By day 3, most people are walking and doing light activity. By day 7, most people are back to normal activities except heavy lifting, which usually waits a week or two longer.

What Should I Do to Prepare for LAA Closure?

Confirm the procedure date and time. Review medication instructions carefully (some anticoagulants continue, others stop). Fast from midnight unless told otherwise. Arrange transportation home for the day of discharge. Stock the house with easy meals and a comfortable spot to rest. Plan to take it easy for a week. Bring photo ID, insurance card, medication list, phone charger, and something to read.

A Week Before

Confirm the procedure date and time. Confirm with your prescribing physician which medications to continue and which to hold. Confirm your fasting instructions. Arrange a ride home for discharge day (you can’t drive after sedation). If you live alone, consider having someone stay with you for the first 24 to 48 hours.

Medications to Discuss

Anticoagulants: depends on your team’s protocol and your specific drug. Some teams continue apixaban or warfarin through the procedure; others hold for 24 to 48 hours. Don’t change anything without explicit instructions.

Antiplatelets: usually continued.

Blood pressure medications: usually continued, though some are held the morning of.

Diabetes medications: adjusted because you’re fasting. Insulin and sulfonylureas need attention. Ask for clear instructions about the morning of the procedure.

Statins, thyroid medications, and most other chronic medications: usually continued without change.

Fasting

Nothing to eat or drink after midnight is the standard instruction. Small sips of water with morning medications are usually permitted. Confirm with your team.

What to Bring to the Hospital

Photo ID and insurance card. List of current medications and doses. Comfortable loose clothing for going home (button-down shirt is easier than pullover after a groin procedure). Phone and charger. Something to read or watch during waiting periods. A small bag for an overnight stay if your team plans observation.

Setting Up the House for Recovery

Stock the fridge with easy-to-prepare meals. Set up a comfortable rest spot with a charging cord, water, snacks, and entertainment. Have ice packs ready for the groin (helps with bruising). Make sure your bathroom is accessible without too many stairs. If you’re on aspirin or other antiplatelets, have an extra pillow handy to elevate the leg if there’s significant bruising.

Arranging Help

You can’t drive home. Sedation makes you unsafe to drive for 24 hours. Arrange a ride. If you live alone, having someone with you for the first day or two helps both for safety and for moral support.

What Happens Day of and Day After?

You’ll arrive at the hospital a couple of hours before the procedure, get sedation or anesthesia, undergo the 60 to 90 minute procedure, recover in a monitored bed for 4 to 6 hours, and either go home that evening or stay overnight. The next morning you’ll have a brief exam and discharge instructions if you stayed overnight. The first week at home is mostly rest, with site care and a few activity restrictions.

Day of the Procedure

Arrive on time. Check in. Change. IV access. Brief team check-in. Move to the procedure room. Get sedation or anesthesia. The procedure runs 60 to 90 minutes. Wake up in recovery. Lie flat for 4 to 6 hours. Eat a light meal when allowed. Decide with the team whether to go home that evening or stay overnight.

The First Night

If you go home, take it easy. Keep the groin dry. Don’t lift more than 5 to 10 pounds. Don’t drive. Sleep normally; the device doesn’t affect sleep position.

If you stay overnight, you’ll be on a heart monitor. The nursing team will check the groin frequently for any bleeding or swelling. Eat normally for dinner if allowed. Sleep as best you can in the hospital.

Day 1 to 2 After

Light activity around the house. Short walks. No driving for 24 to 48 hours. No heavy lifting. The groin will be sore and bruised. Acetaminophen for pain. Avoid NSAIDs for the first few days because they increase bleeding risk.

Day 3 to 7

Most people feel substantially better. Light walking, short outings. Back to desk work for most by day 4 or 5. Continue avoiding heavy lifting and aggressive arm motion until the first follow-up.

Day 7 to 14

Gradual return to normal activity. By day 10 to 14, most people are back to all routine activities except possibly heavy gym work, which waits another week.

Follow-Up Schedule

First follow-up is usually a TEE at 45 days (Watchman FLX) or earlier (Amulet) to confirm initial position and seal. A repeat TEE at 6 months confirms complete sealing and absence of clot on the device. After that, no routine imaging is needed unless symptoms or clinical changes raise concerns.

What Are the Risks of LAA Closure?

LAA closure is generally safe at experienced centers, but it carries real risks. The most common complications are minor: bruising at the groin and mild discomfort. More serious complications are uncommon but include cardiac perforation (about 1 percent), stroke during the procedure (0.5 to 1 percent), and device-related thrombus (clot forming on the device, 1 to 4 percent over time). Long-term, the most important watch-outs are peri-device leak and rare infection.

Common Minor Complications

Bruising at the groin is normal. A palm-sized bruise is common and fades over 2 to 3 weeks. Mild soreness at the access site lasts a few days. Throat soreness from the TEE probe is common and resolves in a day or two. Occasionally, patients have a mild bruise on the chest from the EKG pads or the defibrillator pads placed during the procedure.

Cardiac Perforation

The transseptal puncture and the device deployment involve catheters inside the heart. Rarely (about 1 percent), the catheter or the device perforates the wall of the heart, allowing blood to leak into the sac around the heart. If significant, this is called cardiac tamponade and requires drainage through a needle inserted under the chest wall (pericardiocentesis). The team is set up to recognize and treat this immediately. Most cases are managed without long-term consequences.

Stroke During the Procedure

The procedure involves catheters in the left atrium, where any disruption can dislodge a clot. The risk of procedural stroke is about 0.5 to 1 percent. Pre-procedure TEE rules out any visible clot, and intra-procedural anticoagulation reduces the risk during the procedure itself.

Device Embolization

Rarely, the device dislodges and travels into the atrium, ventricle, or aorta. Modern devices (Watchman FLX with its closed distal end, Amulet with its dual-element design) have substantially reduced this risk to under 1 percent. If it happens, the device usually needs to be retrieved either percutaneously or surgically.

Device-Related Thrombus

After implant, a clot can form on the surface of the device before tissue has covered it. This happens in about 1 to 4 percent of patients at some point during follow-up. It’s usually found on the routine TEE rather than causing a stroke. Treatment is usually a brief return to anticoagulation until the clot resolves, then resuming the standard post-procedure medication plan.

Peri-Device Leak

Some patients have a small gap between the device and the appendage wall, allowing some flow into the appendage. Small leaks (under 5 millimeters) are common and usually clinically insignificant. Larger leaks may require additional intervention or continued anticoagulation. The 6-month TEE assesses for leak.

Infection

Infection of the device is very rare (under 0.1 percent) but serious when it occurs. Strict sterile technique during the procedure and standard antibiotic prophylaxis at procedures afterward (some dental work, certain surgeries) reduce the risk.

Vascular Complications at the Groin

Pseudoaneurysm (a small ballooning at the access vessel), arteriovenous fistula (an abnormal connection between artery and vein), and retroperitoneal hematoma (deep bleeding behind the abdomen) are uncommon but possible. Larger bruises that grow over days, severe back or abdominal pain, or steadily falling blood counts deserve evaluation.

How Do Watchman FLX and Amulet Compare?

Both are FDA-approved for LAA closure. Both prevent stroke at similar rates. The main practical differences are post-procedure anticoagulation (Watchman FLX requires 45 days; Amulet often allows immediate transition to dual antiplatelet alone), device design (Watchman FLX is a single conformable frame; Amulet uses a lobe-and-disc design), and the small differences in complication profile mentioned above. The right device depends on your appendage anatomy and your team’s experience.

Stroke Prevention

The AMULET-IDE trial showed similar stroke prevention at 18 months. Long-term data continues to accumulate. For most patients, either device achieves the main goal of reducing stroke risk to comparable degrees.

Post-Procedure Medication

Watchman FLX: typically 45 days of anticoagulation (warfarin or DOAC) followed by dual antiplatelet therapy (aspirin plus clopidogrel) for the rest of the first 6 months, then aspirin alone indefinitely. The 6-month TEE confirms sealing before the transition.

Amulet: many patients go directly to dual antiplatelet therapy after the procedure, with no post-procedure anticoagulation. The dual antiplatelet typically continues for 1 to 6 months, then transitions to aspirin alone.

If avoiding any post-procedure blood thinner is a high priority (recent major bleed, very high bleeding risk), Amulet has an advantage.

Anatomy Fit

Some appendage shapes fit one device better than the other. The structural heart team uses pre-procedure imaging to assess fit and choose the right device. Some appendages can be closed with either; some are clearly better suited to one.

Operator Experience

Most US structural heart centers have more experience with Watchman than with Amulet, simply because Watchman has been available longer. This is changing as Amulet gains adoption. The most important practical question is: how many of each has the operator placed? Volume matters for procedural safety and success.

Long-Term Data

Watchman has the longest track record. Amulet has good data and a long European track record but less long-term US data. For most patients, this difference doesn’t change the decision, but it’s worth understanding.

When Is Surgical Closure (AtriClip) the Right Choice?

Surgical LAA closure with the AtriClip is the right choice in two main scenarios: when you’re already having cardiac surgery for another reason (CABG, valve replacement, surgical AFib ablation), and when percutaneous devices aren’t suitable because of your appendage anatomy. A stand-alone thoracoscopic AtriClip procedure is more invasive than percutaneous closure but is well-established for selected patients.

LAA Closure During Other Cardiac Surgery

If you’re having coronary artery bypass, valve replacement, or surgical AFib ablation, and you have AFib with elevated stroke risk, the LAAOS III trial showed that adding LAA closure substantially reduces your stroke risk afterward. The clip is placed in a few minutes at the end of the main procedure. The recovery from the heart surgery itself is unchanged. This is now standard at most cardiac surgery centers.

Stand-Alone Surgical Closure

For patients whose appendage anatomy doesn’t accommodate a percutaneous device, a stand-alone thoracoscopic AtriClip procedure is an option. The procedure is done through several small incisions on the left chest. The surgeon places the clip on the appendage from outside the heart under direct visualization. The procedure takes 60 to 90 minutes. Recovery is longer than percutaneous closure, typically 2 to 4 days in the hospital and 2 to 4 weeks at home before full activity.

Why External Closure Is Different

The AtriClip closes the appendage from outside the heart, leaving no foreign body inside the atrium. This eliminates the risk of device-related thrombus (a clot forming on the device inside the heart). It also avoids the transseptal puncture and the manipulation of catheters inside the left atrium. The tradeoff is a more invasive procedure with longer recovery.

Combining Surgical Closure With Other AFib Treatment

Surgical AFib ablation (the Maze procedure or its modifications) is sometimes combined with LAA closure during other cardiac surgery. For patients with persistent or long-standing AFib who are good surgical candidates, this combination can both reduce stroke risk and improve rhythm control.

What Should I Watch for After LAA Closure?

Watch the groin for bleeding, growing bruising, or pain. Watch for chest pain, shortness of breath, signs of stroke, or unusual palpitations. Take medications as prescribed (especially the post-procedure antiplatelet or anticoagulant). Show up for the follow-up TEE. Call the team for any concerning symptoms; go to the ER for severe bleeding, sudden shortness of breath, severe chest pain, or signs of stroke.

When to Call the Office

Call within hours for: new or growing groin swelling; bleeding through the dressing; severe groin pain; fever above 101 Fahrenheit; new chest pain that doesn’t go away; significant shortness of breath; new palpitations that feel different from your baseline; or any concern that’s keeping you up at night.

When to Go to the ER

For: severe bleeding at the groin that doesn’t stop with pressure; sudden severe shortness of breath; chest pain with sweating or nausea; fainting or near-fainting; signs of stroke (sudden weakness, slurred speech, vision loss, severe headache); sudden severe abdominal or back pain; or any symptom that feels emergent.

Signs of Device-Related Thrombus

Most device-related thrombus is found on routine TEE rather than causing symptoms. If you have new stroke symptoms (weakness, slurred speech, vision change) at any point after the procedure, that’s an emergency regardless of timing.

Routine Follow-Up

Show up for the 45-day TEE and the 6-month TEE. These confirm proper sealing and check for any clot on the device. The 6-month TEE is the one that determines whether you can stop dual antiplatelet and go to aspirin alone (Watchman) or finish the dual antiplatelet course (Amulet).

Medications to Continue

Take your post-procedure medications exactly as prescribed. Anticoagulant (Watchman FLX) or dual antiplatelet (Amulet) for the specified period. Don’t stop anything without discussing with your team. The medication plan is what protects you from device-related thrombus during the healing period.

Common Questions Patients Ask Me

Will I be able to stop blood thinners after?

In most cases, yes. After 45 days of post-procedure anticoagulation (Watchman FLX) or immediately (Amulet), patients transition to dual antiplatelet therapy. After 6 months and a TEE confirming sealing, most patients move to aspirin alone for life.

Is one device better than another?

Both Watchman FLX and Amulet have similar stroke prevention efficacy. The choice depends on your appendage anatomy, your need to avoid post-procedure anticoagulation, and your team’s experience with each device. Both are good options when used appropriately.

What if my appendage anatomy doesn’t fit a percutaneous device?

Surgical or thoracoscopic LAA closure with an AtriClip is an option. The decision is made after detailed imaging review with the structural heart team.

How long does the device last?

Permanently. Once tissue covers the device (typically by 6 months), it’s incorporated into the atrial wall and stays for life. No battery, no maintenance, no need to remove or replace.

What if I get a different condition that needs blood thinners?

You can still take anticoagulation if you need it for something else (DVT, PE, mechanical valve, recurrent stroke despite the device). The LAA closure doesn’t preclude anticoagulation; it just makes long-term anticoagulation for AFib stroke prevention unnecessary in most cases.

Will the device cause heart problems?

Once incorporated into the atrial wall, the device doesn’t typically cause functional issues. The appendage’s normal contribution to atrial contraction is small, and its loss doesn’t change cardiac function in any meaningful way. Some studies have looked at small effects on hormonal regulation, but the clinical implications appear minimal.

Will I need follow-up imaging?

Yes. TEE at about 45 days and again at 6 months. After that, no routine imaging is needed unless symptoms or clinical changes raise concerns.

Can I have an MRI with the device?

Yes. Both Watchman FLX and Amulet are MRI-compatible. The clinical MRI fields don’t displace or interfere with these devices.

Why didn’t my doctor mention this option years ago?

LAA closure became FDA-approved in 2015 (Watchman) and 2021 (Amulet). The data and infrastructure for routine offering have built up over time. Many cardiologists are increasingly comfortable referring for LAA closure as evidence and experience have accumulated. If it wasn’t mentioned earlier, it may simply not have been on the differential yet.

Will I have a scar?

A small puncture in the groin, usually no visible scar. If you have a transeptal puncture, that closes on its own inside the heart and doesn’t cause symptoms. AtriClip patients have small scars on the chest from the thoracoscopic incisions.

Can I fly after the procedure?

Short flights are usually fine within a few days. Long flights are usually fine within a week to 10 days. Discuss your specific trip with your team if you have travel coming up.

When can I return to work?

Desk work: 3 to 5 days. Work involving lifting or physical activity: 7 to 14 days. Manual labor: 2 to 3 weeks.

When can I exercise again?

Light walking: within a day. Moderate cardio: within a week. Heavy lifting and high-intensity training: 2 to 3 weeks.

How Should I Think About the Decision?

The decision to pursue LAA closure should be made with a cardiologist who knows your history, a structural heart specialist who has done many of these procedures, and you. The most important questions to answer: is my stroke risk on AFib high enough to justify intervention; is my bleeding risk on blood thinners truly unsustainable; am I a good anatomic candidate for a percutaneous device; and is my overall health good enough to justify the procedural risk? If the answers all point toward the procedure, the next question is which device and which operator.

Getting a Structural Heart Consultation

A structural heart consultation typically involves a review of your medical history, your AFib history, your bleeding history, and your imaging. The team will discuss whether LAA closure is appropriate, which device fits your anatomy, and what the expected procedure and recovery look like. Most consultations also discuss alternatives, including continuing anticoagulation with a different drug, switching from warfarin to a DOAC, or trying additional bleeding-risk reduction strategies before opting for closure.

Picking an Operator

Volume matters. Centers and operators that have done many LAA closures have better procedural safety and success rates than those just starting. Ask: how many LAA closures has the operator done? Does the center routinely offer both Watchman FLX and Amulet? What’s the complication rate at this center?

Getting a Second Opinion

If you’re unsure, a second opinion at a different center is reasonable. LAA closure is a significant procedure, and the decision deserves careful thought.

Reference Tables

Comparison of Percutaneous Devices

LAA Closure vs. Long-Term Anticoagulation

Recovery Timeline After Percutaneous LAA Closure

A Final Note From Me

LAA closure has expanded the options for stroke prevention in AFib patients who can’t tolerate or have failed anticoagulation. The original Watchman has been joined by improved versions (Watchman FLX) and competing devices (Amplatzer Amulet). Surgical options (AtriClip) are well-established during concomitant cardiac surgery, and stand-alone thoracoscopic AtriClip is available for selected patients. The decision about which option is right depends on your appendage anatomy, your bleeding history, your operator’s experience with each device, and the specific clinical context.

If you have AFib with elevated stroke risk and you’ve had significant bleeding on blood thinners, LAA closure is worth a serious conversation. The tradeoff is real: you accept a procedure with its own risks in exchange for being able to stop long-term blood thinners that have already harmed you. For the right patient, the math leans toward the procedure.

If you’re being told LAA closure isn’t right for you, the reasons matter. Some patients are excluded for technical reasons (anatomy, active clot), some for clinical reasons (limited life expectancy, severe other health issues), and some because their actual bleeding risk doesn’t exceed their stroke risk by enough to justify the procedural risk. The conversation about whether closure is right is best had with a structural heart specialist who has experience with the procedure.

If you’ve had LAA closure and you’re recovering, the most important things are following the post-procedure medication plan, completing the follow-up imaging on schedule, and reporting any concerning symptoms promptly. The vast majority of patients have uncomplicated recoveries and return to normal activities within a few weeks. Long-term, you continue to address your other cardiac risk factors and your underlying AFib management.

If you have questions about whether LAA closure makes sense for you, or you’ve already had the procedure and want to talk through expectations or follow-up, our office can help. We work with the structural heart specialists at San Diego Cardiovascular Associates, who do these procedures routinely. To get in touch, visit our practice website.

References

1. Holmes, David R., Saibal Kar, Matthew J. Price, et al. “Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation versus Long-Term Warfarin Therapy: The PREVAIL Trial.” Journal of the American College of Cardiology 64, no. 1 (2014): 1-12.

2. Lakkireddy, Dhanunjaya, Andre A. Thaler, Christopher R. Ellis, et al. “Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman Device for Stroke Prevention in Atrial Fibrillation: A Randomized Controlled Trial.” Circulation 144, no. 19 (2021): 1543-1552.

3. Whitlock, Richard P., Emilie P. Belley-Cote, Domenico Paparella, et al. “Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.” New England Journal of Medicine 384, no. 22 (2021): 2081-2091.

4. Reddy, Vivek Y., Hamid Sievert, Jonathan Halperin, et al. “Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial.” JAMA 312, no. 19 (2014): 1988-1998.

5. Kar, Saibal, Brijeshwar S. Maini, Devi G. Nair, et al. “Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial.” Circulation 143, no. 18 (2021): 1754-1762.

6. January, Craig T., L. Samuel Wann, Hugh Calkins, et al. “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation.” Journal of the American College of Cardiology 74, no. 1 (2019): 104-132.

7. Hindricks, Gerhard, Tatjana Potpara, Nikolaos Dagres, et al. “2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation.” European Heart Journal 42, no. 5 (2021): 373-498.

8. Boersma, Lucas V., Hueseyin Ince, Stephen Kische, et al. “Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-Year Follow-up Outcome Data of the EWOLUTION Trial.” Heart Rhythm 14, no. 9 (2017): 1302-1308.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.